Omeros Corp. (NASDAQ:OMER) stock fell sharply Tuesday after the biotechnology company reported mixed third-quarter 2026 results, with adjusted earnings exceeding Wall Street expectations but revenue falling short.
The company reported adjusted earnings of 6 cents per share, beating the consensus estimate of 3 cents.
Revenue reached $35.93 million, missing the consensus estimate of $37.27 million.
Third-Quarter Financial Results
Omeros reported a net loss of $57.4 million, or 79 cents per share, compared with a net loss of $30.9 million, or 47 cents per share, a year earlier.
The third-quarter results included a noncash loss of $62 million, primarily related to mark-to-market adjustments of a derivative associated with unsecured convertible notes due in 2029.
Adjusted net income rose to $4.7 million, or 6 cents per share, from $1.8 million, or 2 cents per share, in the second quarter.
Operating income reached $4.5 million, compared with an operating loss of $26.4 million a year earlier.
Omeros ended September with $95.3 million in cash and short-term investments. The company generated $13.3 million in positive operating cash flow during the quarter.
Omeros repurchased $30.5 million in principal amount of its 2029 convertible notes for $60.2 million, excluding accrued interest. The transactions reduced the outstanding principal to approximately $40.3 million and eliminated $8.6 million in scheduled interest payments.
Together with earlier stock repurchases, the transactions reduced the number of outstanding or potentially issuable shares by approximately 5.8 million year to date.
Yartemlea Sales Continue to Grow
Yartemlea (narsoplimab-wuug), the first and only approved treatment for stem cell transplant-associated thrombotic microangiopathy (TA-TMA), continued to generate sequential revenue growth.
TA-TMA is a potentially fatal complication of stem cell transplantation.
Yartemlea’s gross revenue increased 30% to $41.8 million in the third quarter from $32.2 million in the second quarter.
Net revenue rose 26% to $35.9 million from $28.5 million in the prior quarter. However, the gross-to-net adjustment increased to 14% from 11.5%.
The company attributed the higher gross-to-net adjustment to increased purchases by entities covered by the 340B Drug Pricing Program, reflecting broader customer adoption and increased outpatient use.
Yartemlea’s New Technology Add-on Payment designation took effect Oct. 1. Eligible hospitals can receive up to $287,079 in additional Medicare reimbursement per eligible inpatient case involving the drug.
Omeros Plans to Expand Yartemlea’s Clinical Development
Omeros expects to support two investigator-initiated or company co-sponsored studies evaluating Yartemlea.
One study will evaluate the drug in patients with hyperinflammatory acute respiratory distress syndrome. The other will assess its ability to prevent TA-TMA in high-risk pediatric transplant patients.
Both open-label, single-arm studies will use historical controls. Each study aims to enroll approximately 50 to 60 patients.
Omeros expects the studies to begin in late 2026 or early 2027, subject to institutional review board and ethics committee approvals.
The company is also exploring additional applications for Yartemlea in conditions involving blood vessel damage, lectin pathway activation or inflammation associated with blood clotting.
Novo Collaboration Offers Additional Growth Opportunities
Omeros said Novo Nordisk A/S (NYSE:NVO) remains on track to initiate a Phase 3 trial of zaltenibart, an antibody it acquired from Omeros in 2025.
Omeros remains eligible for more than $1.8 billion in development and commercial milestone payments, including up to $100 million in near-term payments, plus tiered royalties on net sales.
European Regulatory Setback
In October, the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a negative opinion on Omeros’ application to market narsoplimab for TA-TMA.
The decision followed a re-examination of the committee’s original negative opinion in June.
European regulators previously raised concerns about the study design, insufficient evidence of the drug’s effectiveness and limited pediatric data.
Omeros also announced plans in October to end its compassionate-use program amid rising U.S. demand. The company is working to provide fully reimbursed, named-patient access in Europe and other regions where permitted.
Meanwhile, the U.S. Food and Drug Administration approved Yartemlea in December 2025 to treat TA-TMA in adults and children ages 2 and older.
OMER Price Action: Omeros shares were down 17.81% at $13.71 at the time of publication on Tuesday. Trading volume reached 2.57 million shares, about 65.5% above the 100-day average of 1.55 million shares, according to Benzinga Pro data.
Image via Shutterstock
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.





